A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

NCT03929666 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

74

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Interventions

DRUG: ZW25 (Zanidatamab)
DRUG: Capecitabine
DRUG: Cisplatin
DRUG: Fluorouracil
DRUG: Leucovorin
DRUG: Oxaliplatin
DRUG: Bevacizumab
DRUG: Gemcitabine

Sponsor

Jazz Pharmaceuticals